Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab to Test its CD73 Antibody in Combination with Junshi's PD-1 mAb

publication date: Sep 10, 2019

I-Mab Biopharma of Shanghai will collaborate with Junshi Biosciences to test I-Mab's CD73 antibody in combination with Junshi's Tuoyi, the company China-approved PD-1 mAb. The trial will enroll patients with various solid tumor cancers. CD73, a surface enzyme on stromal and cancer cells, is responsible for producing adenosine, which is highly immunosuppressive. Earlier this year, I-Mab partnered with Roche to conduct a similar US trial. The US trial combines TJD5, I-Mab's CD73 antibody, with Roche's PD-1, Tencentriq®. I-Mab believes TJD5 has best-in-class potential. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital